Department of Pathology, Immunology & Laboratory Medicine, University of Florida, Gainesville, FL, USA.
Division of Pathology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
Future Oncol. 2018 Dec;14(29):3073-3083. doi: 10.2217/fon-2018-0287. Epub 2018 Aug 15.
Prostate cancer is a highly prevalent disease with ample spectrum of aggressiveness and treatment options. Low-risk disease can be safely managed by nonintervention strategies, such as active surveillance; however, accurate risk assessment is warranted. Molecular tests have been developed and validated to complement standard clinicopathological parameters and help to improve risk stratification in prostate cancer. Herein, we review selected tissue-based assays, including genomic prostate score, cell cycle progression score and genomic classifier, with particular emphasis on their role in patient risk assessment in a pretreatment setting, in view of their current or potential utilization in active surveillance.
前列腺癌是一种具有广泛侵袭性和治疗选择的高发疾病。低危疾病可以通过非干预策略（如主动监测）安全管理；然而，需要进行准确的风险评估。已经开发和验证了分子测试来补充标准的临床病理参数，并有助于改善前列腺癌的风险分层。在此，我们回顾了一些基于组织的检测方法，包括基因组前列腺评分、细胞周期进展评分和基因组分类器，特别强调了它们在治疗前评估患者风险方面的作用，以及它们在主动监测中的当前或潜在应用。
